The idea was dismissed years ago as too risky a proposition, but scientists in the US are now contemplating to develop an HIV vaccine made of the deadly virus itself.
A team at 'VIRxSYS' of Maryland is planning to inject people with the proposed HIV vaccine, albeit a deactivated version, after successful tests of a similar vaccine against SIV -- simian HIV -- in monkeys, the 'New Scientist' reported.
"We said 'let's use HIV against itself', and that's what we're doing," Gary McGarrity, VIRxSYS's vice president of scientific and clinical affairs, said.
According to the scientists, the new tests in monkeys suggest a vaccine based on HIV itself might be more effective and now they are planning to apply for approval to perform the trials on those people who already carry the virus.
In their experiments on monkeys, the scientists vaccinated monkeys with a vaccine based on a deactivated version of simian HIV called SIV and then six months later injected them with SIV.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
